Roivant Sciences Ltd. (ROIV)
NASDAQ · Healthcare · Biotechnology
Profile
Roivant Sciences Ltd.
- Exchange
- NASDAQ
- Ticker
- ROIV
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- GB
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Key facts
Roivant Sciences Ltd.: key facts
- Roivant Sciences Ltd. (NASDAQ: ROIV) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, Roivant Sciences Ltd. reported revenue of $8.3M and net income of -$299.8M.
- Revenue fell 37.8% a year over the last 4 fiscal years.
- Free cash flow was positive in 0 of the last 5 fiscal years.
- Net income was positive in 1 of the last 5 fiscal years.
- Over the last twelve months, revenue was $7.5M and net income was -$266.2M.
MonkScore
Roivant Sciences Ltd.'s MonkScore
MonkScore
MonkScore range: 10–20
as of October 2026
Sector rank: 542 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth40–50
- Profitability30–40
- Quality10–20
- Market Conviction90–100
- Safety30–40
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Roivant Sciences Ltd.'s annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $7.5M | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M |
| Gross profit | $6.1M | $7.0M | $28.1M | $31.1M | $28.5M | $46.3M |
| Operating income | -$1.4B | -$1.3B | -$1.1B | -$824.9M | -$809.0M | -$1.2B |
| Net income | -$266.2M | -$299.8M | -$172.0M | $4.3B | -$1.0B | -$845.3M |
| Operating cash flow | -$809.4M | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M |
| Capital expenditure | -$4.6M | -$8.2M | -$4.6M | -$1.4M | -$12.7M | -$17.4M |
| Free cash flow | -$814.0M | -$758.6M | -$844.1M | -$766.7M | -$856.1M | -$695.2M |
| Total debt | $107.2M | $107.4M | $100.2M | $499.7M | $481.4M | $283.9M |
| Cash | $1.2B | $1.4B | $2.7B | $6.5B | $1.7B | $2.1B |
Revenue growth a year
- 1-year
- -71.6%
- 3-year
- -36.0%
- 4-year
- -37.8%
Compound growth between fiscal years.
Peers
Similar companies
- Celldex Therapeutics, Inc.NASDAQ:CLDXMonkScore range: 10–20
- Precigen, Inc.NASDAQ:PGENMonkScore range: 20–30
- CG Oncology Inc.NASDAQ:CGONMonkScore range: 20–30
- Stoke Therapeutics, Inc.NASDAQ:STOKMonkScore range: 20–30
- Nautilus Biotechnolgy, Inc.NASDAQ:NAUTMonkScore range: 20–30
- Sarepta Therapeutics, Inc.NASDAQ:SRPTMonkScore range: 20–30
- Twist Bioscience CorporationNASDAQ:TWSTMonkScore range: 20–30
- Agios Pharmaceuticals, Inc.NASDAQ:AGIOMonkScore range: 20–30
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.